Table 3.
Patients using >2 QTc‐prolonging drugs with a known risk of TdP (n = 11)
| Third QTc‐prolonging drug (daily dose) | Patients, n = 11 | Baseline QTc (ms) | Follow‐up QTc (ms) |
|---|---|---|---|
| Citalopram (30 mg) | 1 | 426 | 410 |
| Flecainide (200 mg) | 1 | – | 468 |
| Haloperidol (0.5 mg) | 1 | 421 | 419 |
| Haloperidol (1 mg p.r.n.) | 1 | 419 | 465 |
| Haloperidol (2 mg) | 1 | – | 377 |
| Haloperidol (2 mg) | 1 | 397 | 415 |
| Haloperidol (2 mg) | 1 | 399 | 452 |
| Methadone (10 mg) | 1 | 418 | 407 |
| Sotalol (120 mg) | 1 | 420 | 453 |
| Sotalol (120 mg) | 1 | – | 407 |
| Sotalol (80 mg) | 1 | – | 436 |
p.r.n, pro re nata (as needed); QTc, heart rate‐corrected QT; TdP, torsade de pointes
Bold text refers to patients with QTc prolongation